McKesson Corporation
Business Model Analysis
How McKesson Makes Money
Annual Revenue: $403.4B
McKesson generates revenue primarily through Healthcare Distribution and Services, with roughly $403.4B in annual revenue.
Core Growth Engine: McKesson is concentrating capital on oncology, multispecialty care, and biopharma services, where provider relationships and specialty capabilities can grow faster than traditional wholesale distribution. It is also expa...
Revenue Model & Pricing
McKesson makes money primarily by purchasing and distributing pharmaceuticals and medical products to pharmacies, hospitals, health systems, and other providers. Distribution is a high-volume, thin-margin business, so purchasing terms, logistics efficiency, order accuracy, customer contracts, and working-capital management drive results. The company also earns service revenue through oncology and multispecialty provider platforms, biopharma services, prescription access and affordability tools, third-party logistics, and medical-surgical distribution.
Core Revenue Streams
North American Pharmaceutical
Large majorityU.S. and Canadian drug wholesaling to retail, institutional and independent pharmacy customers, including Health Mart.
Oncology & Multispecialty
Not separately estimatedSpecialty distribution plus practice-management and data services for oncology, retina and other specialty practices.
Prescription Technology Solutions
Small share of revenueCoverMyMeds, Rx Savings Solutions and biopharma access and affordability programs; a higher-margin contributor to operating profit.
Medical-Surgical Solutions
Single-digit shareMedical supplies and logistics for physician offices, long-term care and alternate care sites; being separated as Wellverse.
Growth Strategy
McKesson is concentrating capital on oncology, multispecialty care, and biopharma services, where provider relationships and specialty capabilities can grow faster than traditional wholesale distribution. It is also expanding prescription access and affordability services, completing its exit from Europe, and pursuing a separation of Medical-Surgical Solutions. The objective is a more focused portfolio with better profit growth while preserving the reliability and cash generation of North American pharmaceutical distribution.
How McKesson Makes Money: FAQ
How does McKesson Corporation make money in pharmaceutical distribution?
McKesson operates an ultra-high-volume, low-margin B2B logistics model. It purchases pharmaceuticals and medical supplies in large bulk directly from drug manufacturers at negotiated prices, stores them in state-of-the-art automated distribution centers, and sells/delivers them with next-day service to retail pharmacies, hospitals, and specialty clinics, earning small distribution margins and inventory service fees.
What is McKesson's Prescription Technology Solutions (CoverMyMeds) division?
Prescription Technology Solutions (RxTS), anchored by CoverMyMeds (acquired in 2017), is McKesson's high-margin digital health software platform. It connects biopharma manufacturers, prescribers, pharmacies, and payers to automate electronic prior authorization (ePA), verify co-pay assistance, and accelerate patient access to specialty medications.
How does McKesson's Medical-Surgical Solutions business generate revenue?
McKesson Medical-Surgical distributes over 300,000 medical supply products, including personal protective equipment (PPE), diagnostic testing kits, surgical instruments, and wound care supplies, to non-hospital alternate site facilities, physician practices, ambulatory surgery centers, and home health agencies across North America.
What are McKesson's distribution agreements with major retail pharmacy chains like CVS Health?
McKesson maintains multi-billion-dollar long-term wholesale distribution contracts with major corporate healthcare customers, most notably CVS Health. McKesson serves as the exclusive primary distributor of all branded and generic pharmaceuticals to thousands of CVS retail pharmacies and retail distribution centers across the United States.
What role does McKesson play in specialty pharmaceuticals and biosimilars?
Specialty pharmaceuticals (complex biologic therapies for oncology, immunology, and rare diseases) represent McKesson's fastest-growing segment. McKesson provides end-to-end cold-chain logistics, patient hub support services, clinical trial logistics, and biosimilar distribution through its specialized provider networks and specialty pharmacies.
How does McKesson leverage inventory management and advanced automation in its warehouses?
McKesson operates over 30 large, highly automated US distribution centers equipped with robotic picking systems, automated guided vehicles (AGVs), RFID tracking, and algorithmic inventory forecasting, enabling 99.9%+ order accuracy and overnight delivery to tens of thousands of healthcare providers.
How does McKesson monetize generic pharmaceutical sourcing through ClarusONE?
McKesson operates ClarusONE, a global generic pharmaceutical sourcing joint venture based in London. By aggregating the large generic purchasing volume of McKesson and its international retail partners, ClarusONE negotiates rock-bottom generic drug pricing directly with manufacturers in India, Europe, and the US.
What are fee-for-service distribution agreements versus traditional inventory price arbitrage?
Historically, distributors profited from drug price inflation by holding inventory. Today, McKesson operates primarily on fee-for-service contracts with pharmaceutical manufacturers, earning fixed percentage fees for handling, warehousing, tracking, and rapid delivery regardless of drug price volatility.
How does McKesson make money?
McKesson operates a massive, invisible logistics empire. They do not invent drugs (like Pfizer) and they don't sell directly to consumers (like Walgreens). Instead, they are the "middleman." They buy billions of dollars of drugs from manufacturers in bulk, store them in massive automated warehouses, and distribute them daily to thousands of pharmacies and hospitals. They make money on razor-thin margins (often under 2%), surviving purely on absolute, staggering volume.
Related Monetization Mechanics
Compare revenue streams, unit economics, and business models
Explore McKesson
Core profile pages, founders and related research hubs for this company.